Revenue ($USD): $1,305,300,000
R&D spend: $180,200,000.00
Employees: 2,600
Fiscal year end: 12/31/22
CEO: Jim Hollingshead
Insuletbecame a member of the S&P 500this year, replacing Silicon Valley Bank in March.
The company also receivedFDA clearance for a basal-only insulin delivery systemthis year, expanding the company’s reach within the diabetes patient population.–SW